The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of ...

When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...

Kerros stock plummeted more than 70% premarket Thursday and Truist Securities analysts predict it will remain under pressure ...

Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration ...

Learn how to leverage your end-of-year downtime to document achievements, update your professional presence and prepare for a ...

Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a ...

Pourhassan and Kazempour are awaiting sentencing but could face up to 20 years in prison for each count of securities and ...

On election day, Tuesday, November 5, Americans will choose between former President Donald Trump and current Vice President ...

The EPIC Act has been proposed with bipartisan and industry support to give small molecule drugs the same protection against ...

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

The discontinuation caps off a turbulent development path for izokibep, which in September 2023 produced disappointing ...